{"organizations": [], "uuid": "b0514600378ee8fc4c747f547a4df003173f6da3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-hemispherx-provides-an-update-to-s/brief-hemispherx-provides-an-update-to-stockholders-highlighting-cancer-focus-idUSASC09YZY", "country": "US", "domain_rank": 408, "title": "BRIEF-Hemispherx Provides An Update To Stockholders Highlighting Cancer Focus", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-02T15:46:00.000+03:00", "replies_count": 0, "uuid": "b0514600378ee8fc4c747f547a4df003173f6da3"}, "author": "", "url": "https://www.reuters.com/article/brief-hemispherx-provides-an-update-to-s/brief-hemispherx-provides-an-update-to-stockholders-highlighting-cancer-focus-idUSASC09YZY", "ord_in_thread": 0, "title": "BRIEF-Hemispherx Provides An Update To Stockholders Highlighting Cancer Focus", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "hemispherx biopharma inc", "sentiment": "none"}, {"name": "highlighting cancer focus reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 2, 2018 / 12:48 PM / Updated 13 minutes ago BRIEF-Hemispherx Provides An Update To Stockholders Highlighting Cancer Focus Reuters Staff 1 Min Read\nMay 2 (Reuters) - Hemispherx Biopharma Inc:\n* HEMISPHERX PROVIDES AN UPDATE TO STOCKHOLDERS HIGHLIGHTING CANCER FOCUS AND $10 MILLION BOOKED SINCE START OF YEAR WILL SUPPORT INCREASED PRODUCTION OF AMPLIGEN FOR IMMUNO-ONCOLOGY CLINICAL TRIALS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-02T15:46:00.000+03:00", "crawled": "2018-05-02T16:03:28.002+03:00", "highlightTitle": ""}